胰腺癌免疫治疗的现状及前景

Immunotherapy on Pancreatic Cancer:Current Status and Future Perspectives

胰腺癌(胰腺导管腺癌)是一种恶性程度较高,诊断和治疗都较困难的消化系统恶性肿瘤。近年来,肿瘤免疫治疗在多种肿瘤中如黑色素瘤、膀胱癌、乳腺癌、非小细胞肺癌和肾癌等均取得了令人振奋的治疗效果,但是胰腺癌的免疫治疗策略尚在不断探索中。目前针对胰腺癌独特的肿瘤微环境设计了多种免疫治疗策略,包括强化/提高自身免疫反应(免疫调节剂、单克隆抗体、肿瘤疫苗和细胞治疗)以及抑制肿瘤免疫逃逸(免疫检查点抑制剂和肿瘤微环境)等。本文就胰腺癌免疫治疗的研究进展进行综述,着重探讨PD-1/PD-L1抑制剂在胰腺癌中的应用,并分析免疫治疗联合其他方式治疗胰腺癌的前景。

Pancreatic ductal adenocarcinoma is a malignant digestive system tumor,which is very difficult to diagnose and treat.In recent years,tumor immunotherapy has achieved encouraging therapeutic effects in multiple types of tumor,such as melanoma,bladder cancer,breast cancer,non-small cell lung cancer and kidney cancer.However,immunotherapy strategies of pancreatic cancer still need to be further explored.Various immunotherapy strategies have been designed for the unique tumor microenvironment of pancreatic cancer,including autoimmune response enhancement(immunomodulators,monoclonal antibodies,tumor vaccines,cell therapy)and tumor immune escape suppression(immune checkpoint inhibitors,tumor microenvironment).In this article,we review the research progress of immunotherapy in pancreatic cancer,focus on the application of PD-1/PD-L1 inhibitors in pancreatic cancer,and analyze the prospects of immunotherapy combined with other methods to treat pancreatic cancer.